ZIVO BIOSCIENCE, INC. (OTCMKTS:ZIVO) Files An 8-K Other Events

ZIVO BIOSCIENCE, INC. (OTCMKTS:ZIVO) Files An 8-K Other Events
Item 8.01 Other Events

Story continues below

As part of the terms and conditions of the Option and Collaboration Agreement ( “Agreement”) entered into on December 19, 2013, by and between ZIVO Bioscience, Inc. and a global animal health company (Collaborator), the Registrant is required to conduct a field study, with appropriate controls, to determine if the Registrant’s bioactive compounds exhibit efficacy in addressing bovine mastitis, a common condition afflicting dairy cows that results in milk production losses, as well as analytics to isolate and characterize such bioactive compounds to the satisfaction of the collaborator.

If the terms and conditions of the Agreement are met and subsequent interactions with the Collaborator result in an approved study design and pathogen selection, the Collaborator can, after the field study is completed and 90-day investigation of test results has taken place, commence to evaluate and negotiate a potential option payment to the Registrant to continue licensing deliberations or to further investigate and research the bioactive compounds.

On or about September 6, 2017, the Registrant received final study design approval from Collaborator and officially commenced work on the field study contemplated by the Agreement, also notifying its research partner, Dairy Experts LLC, of same.

On September 11, 2017, the Registrant released a Press Release dated September 11, 2017, a copy of which is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

Exhibit 99.1 – Press Release dated September 11, 2017.


Zivo Bioscience, Inc. Exhibit
EX-99.1 2 f8k091117_ex99z1.htm EXHIBIT 99.1 PRESS RELEASE DATED SEPTEMBER 11,…
To view the full exhibit click here

About ZIVO BIOSCIENCE, INC. (OTCMKTS:ZIVO)

Zivo Bioscience, Inc., formerly Health Enhancement Products, Inc., is a biotechnology company. The Company is engaged in the study, development and commercialization of naturally derived compounds and bioactive molecules created by algal and bacterial hosts. The Company focuses on research and identification of its bioactive ingredients. It focuses to sell natural bioactive ingredients derived from its algae cultures to animal, human and dietary supplement and medical food manufacturers. It is also engaged in development of biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation. It focuses on developing, manufacturing, marketing and selling tests that allow users to optimize personal health and identify future health risks. The Company manufactures algal products and derivatives, and has various product platforms.

An ad to help with our costs